by Jinghong Chen

Eli Lilly and Co. in January said it planned to sell new versions of Humalog Junior KwikPen and Humalog Mix 75-25 at half of their current U.S. list prices. For both insulin products, more than half of covered lives are under the preferred tier/preferred with prior authorization or step therapy and covered tier/covered with PA/ST among commercial health plans, health exchange and Medicaid programs. Novo Nordisk A/S also started to offer generic versions of its frequently prescribed insulin drugs Novolog and Novolog Mix 70-30 at a 50% discount compared to the current list price. The graphics below show how these four medications are covered among commercial health plans, health exchange programs and Medicare and Medicaid programs.

NOTE: The total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 184.3 million, 10.2 million, 46.1 million and 62.1 million, respectively.

SOURCE: Managed Markets Insight & Technology, LLC database as of January 2020.